

1 Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

2

3 Sarah E. Messiah, PhD, MPH^{a,b}, Frances Brito, MS^c, Harold W. Kohl, III, PhD, MSPH^{d,e}, Stacia
4 DeSantis, PhD^c, Melissa Valerio-Shewmaker, PhD^f, Jessica Ross, BSc, Michael D. Swartz,
5 PhD^c, Ashraf Yaseen, PhD^c, Steven H. Kelder, PhD, MPH^d, Shiming Zhang, MS^c, Onyinye S
6 Omega-Njemnobi, MD, PhD^d, Michael O. Gonzalez, MPH^c, Leqing Wu, MS^c, Eric Boerwinkle,
7 PhD^c, David Lakey, M^g, Jennifer A. Shuford, MD^h, Stephen J. Pont, MD^h

8

9 **Affiliations:** ^aThe University of Texas Health Science Center at Houston, School of Public
10 Health in Dallas, Dallas, TX, USA; ^bCenter for Pediatric Population Health, The University of
11 Texas Health Science Center at Houston, School of Public Health and Children's Health System
12 of Texas, Dallas, TX, USA; ^cThe University of Texas Health Science Center at Houston, School
13 of Public Health in Houston, Houston, TX, USA; ^dThe University of Texas Health Science
14 Center at Houston, School of Public Health in Austin, Austin, TX, USA; ^eUniversity of Texas at
15 Austin, Austin, TX, USA; ^fThe University of Texas Health Science Center at Houston, School of
16 Public Health in Brownsville, Brownsville, TX, USA; ^gThe University of Texas System, Austin,
17 TX, USA; ^hTexas Department of State Health Services, Austin, TX, USA

18

19 **Address correspondence to:** Sarah E. Messiah, The University of Texas Health Science Center
20 at Houston, School of Public Health in Dallas, 2777 N Stemmons Fwy, Dallas, TX
21 (Sarah.E.Messiah@uth.tmc.edu), 972-546-2919

22

23 **Short title:** SARS-CoV-2 Antibody Durability from Natural Infection

24

25 **Conflict of Interest Disclosures (includes financial disclosures):** We have no disclosures to
26 report, financial or otherwise

27

28 **Funding Support:** Texas Department of State Health Services (Contract #HHS000866600001).

29

30 **Role of Funder:** The Texas Department of State Health Services (DSHS) had no role in the
31 study design, data collection and analysis. Drs. Pont and Shuford are DSHS collaborators on this
32 project. They assisted in the interpretation of data, in the writing of this report, and in the
33 decision to submit this paper for publication.

34

35 **Clinical Trials Registration:** N/A

36

37

38

39

40

41

42

43

44

45 **Abbreviations:**

46

47 **COVID-19:** coronavirus disease 2019

48 **DSHS:** Department of State Health Services

49 **SARS-CoV-2:** severe acute respiratory syndrome coronavirus 2

50 **Texas CARES:** Texas COVID-19 Antibody Response Survey

51

52

53

54

WITHDRAWN
see manuscript DOI for details

55 **Contributors' Statement Page**

56 Drs. Boerwinkle, Lakey, Pont, Shuford, and Valerio-Shewmaker conceptualized and designed
57 the Texas CARES study.

58 Dr. Messiah drafted the initial manuscript and reviewed and revised the manuscript based on all
59 other authors input.

60 Drs. Shewmaker, Kohl and Kelder and Jessica Ross designed the data collection instruments and
61 collected data. Michael Gonzalez programmed all survey questions in REDCap.

62 Frances Brito carried out the initial analyses and reviewed and revised the manuscript. Drs.
63 DeSantis, Swartz and Yaseen reviewed all analyses.

64 Leqing Wu, Shiming Zhang and Dr. Omega-Njemnobi coordinated and supervised data
65 collection, and critically reviewed the manuscript for important intellectual content.

66 All authors approved the final manuscript as submitted and agree to be accountable for all
67 aspects of the work.

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

WITHDRAWN
see manuscript DOI for details

85

Abstract

86 **Background.** Recent data suggest the SARS-CoV-2 Delta (B.1.617.2) variant is more
87 transmissible among children compared to the Alpha (B.1.1.7) variant. The true incidence and
88 longitudinal presence of antibody response to SARS-CoV-2 infection is not known, however.
89 We provided estimates of antibody response using Texas Coronavirus Antibody REsponse
90 Survey (Texas CARES) data, a prospective population-based seroprevalence project designed to
91 assess antibody status over time among the general population throughout the state.

92 **Methods.** In October 2020 Texas CARES began enrolling adults (aged 20-80 years) and children
93 (aged 5-19 years). Participants were offered a series of three SARS-CoV-2 antibody tests over 6-
94 8 months, or every 2-3 months that includes the immunoassay for detection of antibodies to the
95 SARS-CoV-2 nucleocapsid protein (Roche N-test). Descriptive characteristics and COVID-19
96 infection-related symptom status was determined by questionnaire at the time of enrollment and
97 prior to each successive blood draw. This analysis included participants ages 5-to-19 years old
98 who have completed all three antibody assessments.

99 **Results.** From our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of
100 nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later
101 (mean 7.0 months, SD 0.97). There was no difference in the presence of antibodies by symptom
102 status (asymptomatic versus symptomatic) or severity (mild-moderate versus severe), sex, age
103 group, or body mass index group (underweight, healthy weight, overweight, obesity) over the
104 three antibody measurement timepoints.

105 **Conclusions.** These results suggest that infection-induced antibodies persist and thus may
106 provide some protection against future infection for at least half a year. 57.9% of the sample
107 were negative for infection-induced antibodies at their third measurement point, suggesting a
108 significant proportion of children have still not acquired natural infection.

109

110

111

112

113

114

115

116

117

118 **Introduction**

119 As of November 11, 2021 more than 6.6 million children in the United States have tested
120 positive for COVID-19.¹ In early September, child COVID-19 cases peaked at 252,000 new
121 cases per week and have declined since but remain extremely high. Since the first week of
122 September, there have been almost 1.5 million additional child cases.¹ These recent data suggest
123 the delta (B.1.617.2) variant is more transmissible among children compared to the alpha (
124 B.1.1.7) variant.¹ These data are particularly troubling as they coincide with school openings
125 across the country. Information about the durability of SARS-CoV-2-specific natural immune
126 responses in children is important to inform school-and community-based transmission
127 mitigation and pediatric vaccination strategies. However, the true incidence and longitudinal
128 presence of antibody response to SARS-CoV-2 infection is not known in the pediatric population
129 due to the high proportion of asymptomatic infection² and prioritization of testing for adults and
130 those with severe illness early in the pandemic.

131 **Methods**

132 The Texas Coronavirus Antibody REsponse Survey (Texas CARES) is an ongoing prospective
133 population-based seroprevalence project designed to assess antibody status over time among a
134 volunteer population throughout the state. The design of Texas CARES has been described
135 previously^{2,3,4} but briefly, includes adults (aged 20-80 years) and children (aged 5-19 years).
136 Texas CARES enrollment commenced in October 2020. Participants ages 5-to-19 years were
137 recruited from large pediatric healthcare systems, Federally Qualified Healthcare Centers, urban
138 and rural pediatric and family medicine practices, health insurance providers, and a social media
139 campaign throughout the state of Texas. Participants were offered a series of three SARS-CoV-2
140 antibody tests over 6-8 months, or every 2-3 months, that includes the immunoassay for

141 detection of antibodies to the SARS-CoV-2 nucleocapsid protein (Roche N-test). The
142 nucleocapsid test uses whole blood and has a sensitivity and specificity exceeding 97%.^{5,6}
143 Descriptive characteristics and COVID-19 infection-related symptom status were determined by
144 questionnaire at the time of enrollment and prior to each successive blood draw. This analysis
145 included participants ages 5-to-19 years old who have completed all three antibody assessments.
146 The presence of SARS-CoV-2 nucleocapsid protein antibodies across the three test timepoints
147 was explored via generalized linear mixed models with a logit link. Random effects for each
148 participant were univariately fit. A likelihood ratio test was performed comparing each model to
149 the intercept-only model to obtain a p-value. All protocols were reviewed and approved by the
150 University of Texas Health Science Center's Committee for the Protection of Human Subjects,
151 but also deemed public health practice by the Texas Department of State Health Services IRB.

152 **Results**

153 From our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of
154 nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later
155 (mean 7.0 months, SD 0.97). Two children seroconverted from positive to negative status
156 between their first and second antibody test. Ten children seroconverted from negative to
157 positive between their first and second antibody test, and six between their second and third tests,
158 respectively. There was no difference in the presence of antibodies by symptom status
159 (asymptomatic versus symptomatic) or severity (mild-moderate versus severe), sex, age group, or
160 body mass index group (underweight, healthy weight, overweight, obesity) over the three
161 antibody measurement timepoints. (Table 1)

162 N-test values to detect the presence of IgM, IgG, or IgA antibodies increased from baseline to
163 timepoint two and then decreased by the third immunoassay assessment. The subsequent

164 downward trend was significant between timepoints 1 and 3 ($P=0.007$) and timepoints 2 and 3
165 ($P<0.001$) (Figure1).

166 **Discussion**

167 The data reported here show that the majority of children followed for > six months and
168 who had three successive antibody test results available for analysis retained SARS-CoV-2
169 antibodies over the entire time period regardless of age, sex, COVID-19 symptom status and
170 severity, and body mass index. These results suggest that infection-induced antibodies persist
171 and thus may provide some protection against future infection for at least half a year. We were
172 unable to confirm COVID-19 infection prior to the baseline assessment, thus these data cannot
173 confirm durability beyond six months. It should also be noted that well over half (57.9%) of the
174 sample were negative for infection-induced antibodies at their third measurement point,
175 suggesting a significant proportion of children are still immune-naïve to SARS-CoV-2 due to
176 natural infection. As such, vaccines have an important role to play in providing protection
177 against COVID-19 for children aged 12 years and older, and for those < 12 years as they become
178 eligible.

179

180

181 **Acknowledgements:**

182 This work was supported by the Texas Department of State Health Services and the University
183 of Texas System. We would like to acknowledge the University of Texas Health Science Center
184 at Houston, School of Public Health's Texas CARES investigative team for their contribution to
185 participant recruitment, data collection, statistical analysis, and data visualization including
186 Sarah E Messiah, PhD; Melissa Valerio-Shewmaker, PhD, MPH; Steven Kelder, PhD, MPH;
187 Harold W Kohl, PhD; Kimberly Aguilard, DrPH; Michael Swartz, PhD; Stacia DeSantis, PhD;
188 Ashraf Yaseen, PhD; Luis León-Novelo, PhD; Eric Boerwinkle, PhD; Jessica Ross, BS; Frances
189 Brito, MS; Michael Gonzalez, MS; Leqing Wu, PhD; Onyinye Omega Njemnobi, MBBS, MPH;
190 Shiming Zhang, MS; Joy Yoo, BS; Tianyao Hao, MS; Cesar Pinzon Gomez, MD; Karina Farias,
191 BA; Ashleigh Gil, MPH; David Lakey, MD; Jennifer Shuford, MD, MPH; Stephen Pont, MD,
192 MPH. This analysis would not have been possible without the partnership of many.

193
194 The TX CARES investigation team would like to thank Children's Health System of Texas,
195 Dallas, TX; Cook Children's Forth Worth, TX; Covenant Health, Lubbock, TX; Driscoll
196 Children's, Corpus Christi, TX; El Paso Children's, El Paso, TX; UTHealth McGovern,
197 Houston, TX; UTHealthRGV, Rio Grande Valley, TX; UTHealth Tyler, Tyler, TX; Ascension
198 Health, Privia Health, Superior Health Plan, TX Association of Family Physicians, TX Medical
199 Association, TX Pediatric Society, and Federally Qualified Health Care Centers statewide, for
200 assisting with sharing information with families about this survey.

201
202
203 **Data Sharing Statement**

204 Texas CARES investigators are committed to data sharing. Granular results and user-specified
205 data summaries are currently publicly available on the Texas CARES portal
206 (<https://sph.uth.edu/projects/texascares/dashboard>). When baseline recruitment is complete, a
207 deidentified individual level dataset will be available for download from the same portal.

208

209

210

211

212

213

214

215

216

217

218

219 **References**

- 220 1. American Academy of Pediatrics and the Children’s Hospital Association. Children and
221 COVID-19: State Data Report. [https://www.aap.org/en/pages/2019-novel-coronavirus-](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/)
222 [covid-19-infections/children-and-covid-19-state-level-data-report/](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/) Accessed November
223 12, 2021.
- 224 2. Messiah SE, Valerio-Shewmaker MA, DeSantis, SM, et al. Estimated Prevalence of
225 SARS-CoV-2 Antibodies in the Texas Pediatric Population, 2021. Preprints with the
226 *Lancet*. Available at SSRN: <http://dx.doi.org/10.2139/ssrn.3868061>
- 227 3. Valerio-Shewmaker MA, DeSantis SM, et al. Strategies to estimate prevalence of SARS-
228 CoV-2 antibodies in a Texas vulnerable population: results from phase I of the Texas
229 Coronavirus Antibody REsponse Survey (TX CARES). medRxiv [Preprint]. 2021 Jul
230 medRxiv doi: <https://doi.org/10.1101/2021.08.04.21261613>
- 231 4. DeSantis SM, León-Novelo LG, Swartz MD, et al. Estimation of total immunity to
232 SARS-Cov-2 in Texas. medRxiv [Preprint]. 2021 medRxiv doi:
233 <https://doi.org/10.1101/2021.08.05.21261610>
- 234 5. Roche. Elecsys® Anti-SARS-CoV-2. Package Insert 2020-07, V9.0; Material Numbers
235 09203095190 and 09203079190. US Food and Drug Administration
236 <https://www.fda.gov/media/137605/download>
- 237 6. Roche. Elecsys® Anti-SARS-CoV-2 S. Package Insert 2020-12, V1.0; Material
238 Numbers 09289267190 and 09289275190. US Food and Drug Administration
239 <https://www.fda.gov/media/144037/download>

241

242

243

244

245

246

247

248

249

250

251

252

253

254 **Table 1. Sars-CoV-2 antibody status over 3 timepoints (each separated by 2-3 months) by**
 255 **symptom status and severity and descriptive characteristics.**
 256

| | Timepoint 1 (N=159) | | Timepoint 2 (N=159) | | Timepoint 3 (N=159) | | p-value ^a |
|--|------------------------|-------------|------------------------|------------|------------------------|------------|----------------------|
| | Positive | Negative | Positive | Negative | Positive | Negative | |
| | 53 (33.3%) | 106 (66.6%) | 61 (38.4%) | 98 (61.6%) | 67 (42.1%) | 92 (57.9%) | |
| Symptom Status | | | | | | | 0.498 |
| Symptomatic | 25 (50.0%) | 30 (29.4%) | 26 (44.8%) | 29 (30.9%) | 26 (40.6%) | 29 (33.0%) | |
| Asymptomatic | 25 (50.0%) | 72 (70.6%) | 32 (55.2%) | 65 (69.1%) | 38 (59.4%) | 59 (67.0%) | |
| Missing | 3 | 4 | 3 | 4 | 3 | 4 | |
| Symptom Severity^b | | | | | | | 0.872 |
| Mild-Moderate | 21 (87.5%) | 24 (80.0%) | 21 (84.0%) | 24 (82.8%) | 21 (84.0%) | 24 (82.8%) | |
| Severe | 3 (12.5%) | 6 (20.0%) | 4 (16.0%) | 5 (17.2%) | 4 (16.0%) | 5 (17.2%) | |
| Sex | | | | | | | 0.942 |
| Males | 22 (42.3%) | 43 (40.6%) | 25 (41.7%) | 40 (40.8%) | 28 (42.4%) | 37 (40.2%) | |
| Females | 30 (57.7%) | 63 (59.4%) | 35 (58.3%) | 58 (59.2%) | 38 (57.6%) | 55 (59.8%) | |
| Age Group | | | | | | | 0.977 |
| 5-9 years | 15 (28.3%) | 23 (21.7%) | 16 (26.2%) | 22 (22.4%) | 17 (25.4%) | 21 (22.8%) | |
| 10-14 years | 20 (37.7%) | 48 (45.3%) | 25 (41.0%) | 43 (43.9%) | 30 (44.8%) | 38 (41.3%) | |
| 15-19 years | 18 (34.0%) | 35 (33.0%) | 20 (32.8%) | 33 (33.7%) | 20 (29.9%) | 33 (35.9%) | |
| Body Mass Index Group^c | | | | | | | 0.117 |
| Underweight | 1 (2.1%) | 4 (4.0%) | 1 (1.8%) | 4 (4.3%) | 2 (3.3%) | 3 (3.4%) | |
| Healthy | 31 (64.6%) | 66 (65.3%) | 37 (66.1%) | 60 (64.5%) | 40 (65.6%) | 57 (64.8%) | |
| Overweight | 8 (16.7%) | 21 (20.8%) | 10 (17.9%) | 19 (20.4%) | 11 (18.0%) | 18 (20.5%) | |
| Obesity | 8 (16.7%) | 10 (9.9%) | 8 (14.3%) | 10 (10.8%) | 8 (13.1%) | 10 (11.4%) | |
| Missing | 5 | 5 | 5 | 5 | 6 | 4 | |

257

258 ^ap value calculated from likelihood ratio test

259 ^bPercent of symptomatic children total

260 ^cBased on standardized body mass index percentiles adjusted for age and sex

261 (<https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm>)

262

263

264

265


266

267

268

269

270



271 **Figure 1.** Boxplots of N-test values at each time point.

272 Boxplot for the N-test values across the three timepoints for the sample that were positive at the first timepoint
273 (N=53). The N-test value denotes prior COVID-19 infection. Each box represents data falling between the 25th and
274 the 75th percentiles. The horizontal bar within the box represents the median, and the whiskers extend 1.5 times the
275 interquartile range below the 25th and above the 75th percentiles, and the points that lie beyond the whiskers can
276 be considered extreme values.

277 P values calculated by Wilcoxon Signed Rank test. Note that this is not a test for the difference in medians, but
278 rather a non-parametric test for differences in sets of pairs.

279 *significant at the p=0.05 level

280

281